title: Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma             cells.
abstract: In spite of an initially promising anti-tumor activity, oxaliplatin-based             combinatorial treatments can eventually result in a tumor resistance response.             In this study we aimed to understand the role of autophagy in HCC cell resistance             to oxaliplatin and to discuss its potential therapeutic implication. We found             that exposure to oxaliplatin induced a significant increase in LC3 lipidation             and subsequent LC3 puncta formation. While the proliferation of HCC cells was             inhibited upon oxaliplatin exposure, inhibition of autophagy by ATG7 interference             and chloroquine pre-treatment further increased the sensitivity to chemotherapy.             Meanwhile, the oxaliplatin-induced apoptotic cell death was significantly enhanced.             These results suggest that autophagy may function importantly in HepG2 cell resistance             to oxaliplatin. Intriguingly, the resistance could be recovered apparently by             inhibition of autophagy. This also points to the potential therapy for hepatoma             by perturbing autophagy.
authors.affiliation: Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, PR China.
authors.forename: Hailei
authors.initials: H
authors.lastname: Du
authors.forename: Weiping
authors.initials: W
authors.lastname: Yang
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.forename: Mingming
authors.initials: M
authors.lastname: Shi
authors.forename: Varun
authors.initials: V
authors.lastname: Seewoo
authors.forename: Jiayu
authors.initials: J
authors.lastname: Wang
authors.forename: Andy
authors.initials: A
authors.lastname: Lin
authors.forename: Zhuoran
authors.initials: Z
authors.lastname: Liu
authors.forename: Weihua
authors.initials: W
authors.lastname: Qiu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001343:Autophagy / Q000187:drug effects* / Q000502:physiology; D000071193:Autophagy-Related Protein 7; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000473:pathology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000502:physiology; D005455:Fluorescent Antibody Technique; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin; D034741:RNA, Small Interfering; D060888:Real-Time Polymerase Chain Reaction; D014162:Transfection; D044764:Ubiquitin-Activating Enzymes / Q000037:antagonists & inhibitors / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D034741:RNA, Small Interfering; D000077150:Oxaliplatin; C509349:ATG7 protein, human; D000071193:Autophagy-Related Protein 7; D044764:Ubiquitin-Activating Enzymes